CDCA2 antibody
- Known as:
- CDCA2 (anti-)
- Catalog number:
- orb101207
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- CDCA2 antibody
Related genes to: CDCA2 antibody
- Gene:
- CDCA2 NIH gene
- Name:
- cell division cycle associated 2
- Previous symbol:
- -
- Synonyms:
- Repo-Man, PPP1R81
- Chromosome:
- 8p21.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-04-03
- Date modifiied:
- 2014-11-18
Related products to: CDCA2 antibody
Related articles to: CDCA2 antibody
- The cell division cycle-associated () gene family regulates cell cycle progression and is frequently dysregulated in multiple cancers. However, its roles in tumor stemness maintenance and drug sensitivity remain unclear. This study aimed to investigate the expression of the CDCAs in cancers and their associations with tumor stemness and drug sensitivity, with a particular focus on the effects of on stemness and drug sensitivity in lung and colorectal cancers. - Source: PubMed
Publication date: 2026/04/28
Xiang LinPeng TianSong Guo-BinYing Hou-QunCheng Xue-Xin - Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Stage II CRC poses a clinical challenge due to its heterogeneous outcomes, with 15-20% of patients experiencing recurrence. Current prognostic models based on clinicopathologic features lack sufficient precision, highlighting the need for new molecular markers. In this study, we employed an integrative TMT-based proteomics strategy to identify biomarkers of recurrence in stage II CRC. We analyzed paired formalin-fixed paraffin-embedded (FFPE) tissues and small extracellular vesicles (sEVs) from stage II recurrent and nonrecurrent CRC patients. Validation of proteomics data was performed in silico and by WB, immunohistochemistry, ELISA, and in vitro functional cell-based assays. This multifaceted approach identified several dysregulated proteins associated with CRC recurrence, including MANF, TLN1, TALDO1, and CDCA2, among others. CDCA2 knockdown altered the tumorigenic properties of CRC cells in vitro, correlating findings with its association with prognosis. Conversely, higher plasma levels of MANF were found in nonrecurrent CRC patients, aligning results with its favorable prognosis profile. Collectively, our findings support the value of combining paired FFPE tissue and sEVs proteomics analyses to uncover recurrence-associated biomarkers, offering the potential for risk stratification and management of stage II CRC patients. - Source: PubMed
Publication date: 2026/04/12
Rejas-González RaquelFernández-Aceñero María JesúsTirado-Zambrana Pernilla SeidiSanz-Criado LaraDziaková JanaSanz-López RodrigoPoves CarmenFeliu JaimeHeredia-Soto VictoriaMendiola MartaMartínez-Useros JavierPeláez-García AlbertoMontero-Calle AnaBarderas Rodrigo - Cellular myelocytomatosis oncogene (MYC) transcription factors are encoded by a family of genes that include the prototype member MYC, MYCN and MYCL, and most human cancers display expression alterations of MYC genes. MYC is regulated at multiple levels, and its stability and activity are modulated by protein phosphorylation. Although there is a reasonable knowledge of the kinases required for MYC modifications, the counteracting phosphatases have been understudied. Here, we have investigated the role of the chromatin-associated protein phosphatase 1 (PP1) regulatory subunit CDCA2, also known as Repo-Man, in the regulation of MYC proteins in cancer cells. Using RNA interference and degron-mediated degradation of CDCA2, we have demonstrated that the PP1 subunit is required for cMYC and MYCN stabilization and viability of triple-negative breast cancer, neuroblastoma and colon cancer cells. Proximity ligation assays indicate that both cMYC and MYCN are in close proximity to CDCA2 in vivo. Furthermore, we have shown that CDC2A is a bona fide MYC target gene in cancer cells, revealing a reciprocal regulatory loop that could be exploited for therapeutic purposes. - Source: PubMed
Stamatiou KonstantinosLigammari LorenaBothota MalkiTsavou AntoniaGokhan EzgiCicirò YleniaZacarias MarianoSoucek LauraSala ArturoVagnarelli Paola - The difference in molecular characteristics of Triple negative breast cancer (TNBC) aids in distinguishing between its four prominent subtypes- basal-like 1, basal-like 2, mesenchymal, and luminal androgen receptor. This study presents the first integrative framework that combines explainable AI with machine learning approaches to classify TNBC subtypes. Unlike conventional models, our approach offers interpretability while enabling biomarker prioritization by identifying key hub genes that drive subtype-specific predictions. - Source: PubMed
Publication date: 2026/02/22
L Biji CPatel TruptiCharan DevyaniSinha Mangalam GoutamS RupaakJain MedhanshBhardwaj AshutoshGupta AnnanyaJ DheebaK AthiraMishra AnkitaMishra Deepak - Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are a well-known source in the field of regenerative medicine. However, their biological features and perinatal environment are compromised by various conditions, such as preeclampsia. Pregnancy-related complications lead to functional impairments, making the cord-isolated mesenchymal stem cells (MSCs) less efficient in self-renewal and regenerative capacity. Therefore, the purpose of this study was to assess the adhesion, migration, and proliferation potential of hUC-MSCs in preeclamptic conditions. - Source: PubMed
Publication date: 2026/01/04
Rasheed NabilaZahid NishaRazzaq Syeda SaimaSiraj AnumHaneef KanwalMustajab ArhumKaur Jasmeet